Search

Your search keyword '"Woelber, L."' showing total 218 results
Start Over Author "Woelber, L."
218 results on '"Woelber, L."'

3. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Author

Oaknin, A, Gladieff, L, Martínez-García, J, Villacampa, G, Takekuma, M, De Giorgi, U, Lindemann, K, Woelber, L, Colombo, N, Duska, L, Leary, A, Godoy-Ortiz, A, Nishio, S, Angelergues, A, Rubio, M, Fariñas-Madrid, L, Yamaguchi, S, Lorusso, D, Ray-Coquard, I, Manso, L, Joly, F, Alarcón, J, Follana, P, Romero, I, Lebreton, C, Pérez-Fidalgo, J, Yunokawa, M, Dahlstrand, H, D'Hondt, V, Randall, L, Oaknin, Ana, Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, Takekuma, Munetaka, De Giorgi, Ugo, Lindemann, Kristina, Woelber, Linn, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Nishio, Shin, Angelergues, Antoine, Rubio, Maria Jesús, Fariñas-Madrid, Lorena, Yamaguchi, Satoshi, Lorusso, Domenica, Ray-Coquard, Isabelle, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Romero, Ignacio, Lebreton, Coriolan, Pérez-Fidalgo, J Alejandro, Yunokawa, Mayu, Dahlstrand, Hanna, D'Hondt, Véronique, Randall, Leslie M, Oaknin, A, Gladieff, L, Martínez-García, J, Villacampa, G, Takekuma, M, De Giorgi, U, Lindemann, K, Woelber, L, Colombo, N, Duska, L, Leary, A, Godoy-Ortiz, A, Nishio, S, Angelergues, A, Rubio, M, Fariñas-Madrid, L, Yamaguchi, S, Lorusso, D, Ray-Coquard, I, Manso, L, Joly, F, Alarcón, J, Follana, P, Romero, I, Lebreton, C, Pérez-Fidalgo, J, Yunokawa, M, Dahlstrand, H, D'Hondt, V, Randall, L, Oaknin, Ana, Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, Takekuma, Munetaka, De Giorgi, Ugo, Lindemann, Kristina, Woelber, Linn, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Nishio, Shin, Angelergues, Antoine, Rubio, Maria Jesús, Fariñas-Madrid, Lorena, Yamaguchi, Satoshi, Lorusso, Domenica, Ray-Coquard, Isabelle, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Romero, Ignacio, Lebreton, Coriolan, Pérez-Fidalgo, J Alejandro, Yunokawa, Mayu, Dahlstrand, Hanna, D'Hondt, Véronique, and Randall, Leslie M

Abstract

Background: The GOG240 trial established bevacizumab with chemotherapy as standard first-line therapy for metastatic or recurrent cervical cancer. In the BEATcc trial (ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030), we aimed to evaluate the addition of an immune checkpoint inhibitor to this standard backbone. Methods: In this investigator-initiated, randomised, open-label, phase 3 trial, patients from 92 sites in Europe, Japan, and the USA with metastatic (stage IVB), persistent, or recurrent cervical cancer that was measurable, previously untreated, and not amenable to curative surgery or radiation were randomly assigned 1:1 to receive standard therapy (cisplatin 50 mg/m2 or carboplatin area under the curve of 5, paclitaxel 175 mg/m2, and bevacizumab 15 mg/kg, all on day 1 of every 3-week cycle) with or without atezolizumab 1200 mg. Treatment was continued until disease progression, unacceptable toxicity, patient withdrawal, or death. Stratification factors were previous concomitant chemoradiation (yes vs no), histology (squamous cell carcinoma vs adenocarcinoma including adenosquamous carcinoma), and platinum backbone (cisplatin vs carboplatin). Dual primary endpoints were investigator-assessed progression-free survival according to Response Evaluation Criteria in Solid Tumours version 1.1 and overall survival analysed in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT03556839, and is ongoing. Findings: Between Oct 8, 2018, and Aug 20, 2021, 410 of 519 patients assessed for eligibility were enrolled. Median progression-free survival was 13·7 months (95% CI 12·3–16·6) with atezolizumab and 10·4 months (9·7–11·7) with standard therapy (hazard ratio [HR]=0·62 [95% CI 0·49–0·78]; p<0·0001); at the interim overall survival analysis, median overall survival was 32·1 months (95% CI 25·3–36·8) versus 22·8 months (20·3–28·0), respectively (HR 0·68 [95% CI 0·52–0·88]; p=0·0046). Grade 3 or worse adverse events occurred in 79% of patient

Published
2024

5. VP5-2023: Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)

Author

Oaknin, A., primary, Gladieff, L., additional, Martinez-Garcia, J., additional, Villacampa, G., additional, Takekuma, M., additional, De Giorgi, U.F.F., additional, Lindemann, K., additional, Woelber, L., additional, Colombo, N., additional, Duska, L.R., additional, Leary, A., additional, Godoy Ortiz, A., additional, Nishio, S., additional, Angelergues, A., additional, Rubio Perez, M.J., additional, Fariñas Madrid, L., additional, Yamaguchi, S., additional, Lorusso, D., additional, D'Hondt, V., additional, and Randall, L., additional

Published
2023
Full Text
View/download PDF

8. Risiko für eine pelvine Metastasierung und Stellenwert der pelvinen Lymphonodektomie bei Patientinnen mit nodal-positivem Vulvakarzinom – Ergebnisse der AGO-VOP.2/QS Vulva Studie

Author

Jaeger, A, additional, Hampl, M, additional, Zu Eulenburg, C, additional, Prieske, K, additional, Hambrecht, J, additional, Fuerst, S, additional, Klapdor, R, additional, Heublein, S, additional, Gass, P, additional, Rohner, A, additional, Canzler, U, additional, Becker, S, additional, Bommert, M, additional, Bauerschlag, D, additional, Denecke, A, additional, Hanker, L, additional, Runnebaum, I, additional, Forner, DM, additional, Schochter, F, additional, Klar, M, additional, Schwab, R, additional, Koepke, M, additional, Kalder, M, additional, Hantschmann, P, additional, Ratiu, D, additional, Denschlag, D, additional, Schroeder, W, additional, Tuschy, B, additional, Baumann, K, additional, Mustea, A, additional, Soergel, P, additional, Bronger, H, additional, Bauerschmitz, G, additional, Kosse, J, additional, Koch, MC, additional, Ignatov, A, additional, Sehouli, J, additional, Dannecker, C, additional, Mahner, S, additional, and Woelber, L, additional

Published
2022
Full Text
View/download PDF

9. 533P Real-world data of treatment and outcome of patients with relapsed ovarian cancer (OC) in Germany (QS ovar of the AGO study group)

Author

Harter, P., primary, du Bois, A., additional, Hilpert, F., additional, Kerkmann, M., additional, Sehouli, J., additional, Mahner, S., additional, de Gregorio, N., additional, Hanker, L., additional, Heitz, F., additional, Marmé, F., additional, Woelber, L., additional, Holtmann, L., additional, Elser, G., additional, and Pfisterer, J., additional

Published
2022
Full Text
View/download PDF

10. 561P When to treat the pelvis in node-positive vulvar cancer: Results from the AGO-VOP.2 QS vulva study

Author

Hampl, M., primary, Jaeger, A., additional, Eulenburg, C., additional, Prieske, K., additional, Hambrecht, J., additional, Fuerst, S., additional, Klapdor, R., additional, Heublein, S., additional, Gass, P., additional, Rohner, A., additional, Canzler, U., additional, Becker, S., additional, Bommert, M., additional, Bauerschlag, D., additional, Denecke, A., additional, Hanker, L., additional, Sehouli, J., additional, Dannecker, C., additional, Mahner, S., additional, and Woelber, L., additional

Published
2022
Full Text
View/download PDF

11. 604P T cell density and immune phenotypes at the invasive margin correlate with prognosis in epithelial vulvar cancer

Author

Woelber, L., primary, Blessin, N.C., additional, Rolschewski, A-C., additional, Lutz, F., additional, Mandelkow, T., additional, Yang, C., additional, Bady, E., additional, Reiswich, V., additional, Simon, R., additional, Sauter, G., additional, Mahner, S., additional, De Gregorio, N., additional, Kalder, M., additional, Klapdor, R., additional, Braicu, I., additional, Fuerst, S., additional, Klar, M., additional, Strauß, H-G., additional, Burandt, E., additional, and Prieske, K., additional

Published
2022
Full Text
View/download PDF

12. Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study

Author

Trillsch, F., Mahner, S., Woelber, L., Vettorazzi, E., Reuss, A., Ewald-Riegler, N., de Gregorio, N., Fotopoulou, C., Schmalfeldt, B., Burges, A., Hilpert, F., Fehm, T., Meier, W., Hillemanns, P., Hanker, L., Hasenburg, A., Strauss, H.G., Hellriegel, M., Wimberger, P., Baumann, K., Keyver-Paik, M.D., Canzler, U., Wollschlaeger, K., Forner, D., Pfisterer, J., Schroeder, W., Muenstedt, K., Richter, B., Kommoss, F., Hauptmann, S., and du Bois, A.

Published
2014
Full Text
View/download PDF

14. Risk of pelvic metastasis and significance of pelvic lymphadenectomy in patients with node-positive vulvar cancer - results of the AGO-VOP.2/QS vulva study

Author

Jaeger, A., Hampl, M., Zu Eulenburg, C., Prieske, K., Hambrecht, J., Fuerst, S., Klapdor, R., Heublein, S., Gass, P., Rohner, A., Canzler, U., Becker, S., Bommert, M., Bauerschlag, D., Denecke, A., Hanker, L., Runnebaum, I, Forner, D. M., Schochter, F., Klar, M., Schwab, R., Koepke, M., Kalder, M., Hantschmann, P., Ratiu, D., Denschlag, D., Schroeder, W., Tuschy, B., Baumann, K., Mustea, A., Soergel, P., Bronger, H., Bauerschmitz, G., Kosse, J., Koch, M. C., Ignatov, A., Sehouli, J., Dannecker, C., Mahner, S., Woelber, L., Jaeger, A., Hampl, M., Zu Eulenburg, C., Prieske, K., Hambrecht, J., Fuerst, S., Klapdor, R., Heublein, S., Gass, P., Rohner, A., Canzler, U., Becker, S., Bommert, M., Bauerschlag, D., Denecke, A., Hanker, L., Runnebaum, I, Forner, D. M., Schochter, F., Klar, M., Schwab, R., Koepke, M., Kalder, M., Hantschmann, P., Ratiu, D., Denschlag, D., Schroeder, W., Tuschy, B., Baumann, K., Mustea, A., Soergel, P., Bronger, H., Bauerschmitz, G., Kosse, J., Koch, M. C., Ignatov, A., Sehouli, J., Dannecker, C., Mahner, S., and Woelber, L.

Published
2022

15. EPV255/#120 Tisotumab vedotin vs investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovatv 301/ENGOT-CX12/GOG-3057, trial in progress)

Author

Vergote, I, primary, Randall, LM, additional, Kalbacher, E, additional, Madsen, K, additional, Van Nieuwenhuysen, E, additional, González-Martín, A, additional, Cibula, D, additional, Monk, B, additional, Woelber, L, additional, Banerjee, S, additional, Westermann, A, additional, Colombo, N, additional, Lorusso, D, additional, Calvert, P, additional, Coleman, RL, additional, Marth, C, additional, Soumaoro, I, additional, Jain, S, additional, and Slomovitz, B, additional

Published
2021
Full Text
View/download PDF

20. LBA9 innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer

Author

Vergote, I.B., Gonzalez Martin, A., Fujiwara, K., Kalbacher, E., Bagameri, A., Ghamande, S., Lee, J-Y., Banerjee, S., Maluf, F.C., Lorusso, D., Yonemori, K., Van Nieuwenhuysen, E., Manso Sanchez, L.M., Woelber, L., Westermann, A.M., Covens, A., Whalley, E., Teng, M.S.L., Soumaoro, I., and Slomovitz, B.M.

Published
2023
Full Text
View/download PDF

23. Importance of pelvic Lymphonodectomy in Squamous Cell Carcinoma of the Vulva (VSCC) Subgroup Analysis of the AGO-CaRE-1 Study

Author

Jueckstock, J., Fuerst, S., Bommert, M., Harter, P., Prieske, K., Eulenburg, C., Hilpert, F., deGregorio, N., Iborra, S., Sehouli, J., Ignatov, A., Hillemanns, P., Jaeger, A., Strauss, H-G, Baumann, K., Thiel, F., Mustea, A., Meier, W., Wimberger, P., Hanker, L., Schmalfeldt, B., Canzler, U., Fehm, T., Luyten, A., Hellriegel, M., Kosse, J., Heiss, C., Hantschmann, P., Mallmann, P., Tanner, B., Pfisterer, J., Woelber, L., Mahner, S., Jueckstock, J., Fuerst, S., Bommert, M., Harter, P., Prieske, K., Eulenburg, C., Hilpert, F., deGregorio, N., Iborra, S., Sehouli, J., Ignatov, A., Hillemanns, P., Jaeger, A., Strauss, H-G, Baumann, K., Thiel, F., Mustea, A., Meier, W., Wimberger, P., Hanker, L., Schmalfeldt, B., Canzler, U., Fehm, T., Luyten, A., Hellriegel, M., Kosse, J., Heiss, C., Hantschmann, P., Mallmann, P., Tanner, B., Pfisterer, J., Woelber, L., and Mahner, S.

Published
2020

24. The influence of age on treatment and prognosis of patients with squamous cell vulvar cancer (VSCC)- a subset analysis of the AGO-CaRE-1 study

Author

Prieske, K., Woelber, L., Muallem, M. Z., Eulenburg, C., Jueckstock, J., Hilpert, F., de Gregorio, N., Iborra, S., Ignatov, A., Hillemanns, P., Fuerst, S. T., Strauss, H. G., Baumann, K., Thiel, F., Mustea, A., Meier, W., Harter, P., Wimberger, P., Hanker, L., Schmalfeldt, B., Canzler, U., Fehm, T., Luyten, A., Hellriegel, M., Kosse, J., Heiss, C., Hantschmann, P., Mallmann, P., Tanner, B., Pfisterer, J., Sehouli, J., Mahner, S., Prieske, K., Woelber, L., Muallem, M. Z., Eulenburg, C., Jueckstock, J., Hilpert, F., de Gregorio, N., Iborra, S., Ignatov, A., Hillemanns, P., Fuerst, S. T., Strauss, H. G., Baumann, K., Thiel, F., Mustea, A., Meier, W., Harter, P., Wimberger, P., Hanker, L., Schmalfeldt, B., Canzler, U., Fehm, T., Luyten, A., Hellriegel, M., Kosse, J., Heiss, C., Hantschmann, P., Mallmann, P., Tanner, B., Pfisterer, J., Sehouli, J., and Mahner, S.

Published
2020

25. BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis

Author

Kalachand, RD, Stordal, B, Madden, S, Chandler, B, Cunningham, J, Goode, EL, Ruscito, I, Braicu, E, Sehouli, J, Ignatov, A, Yu, H, Katsaros, D, Mills, GB, Lu, KH, Carey, MS, Timms, KM, Kupryjanczyk, J, Rzepecka, IK, Podgorska, A, McAlpine, JN, Swisher, EM, Bernards, SS, O'Riain, C, O'Toole, S, O'Leary, JJ, Bowtell, DD, Thomas, DM, Prieske, K, Joosse, SA, Woelber, L, Chaudhry, P, Hafner, N, Runnebaum, IB, Hennessy, BT, Kalachand, RD, Stordal, B, Madden, S, Chandler, B, Cunningham, J, Goode, EL, Ruscito, I, Braicu, E, Sehouli, J, Ignatov, A, Yu, H, Katsaros, D, Mills, GB, Lu, KH, Carey, MS, Timms, KM, Kupryjanczyk, J, Rzepecka, IK, Podgorska, A, McAlpine, JN, Swisher, EM, Bernards, SS, O'Riain, C, O'Toole, S, O'Leary, JJ, Bowtell, DD, Thomas, DM, Prieske, K, Joosse, SA, Woelber, L, Chaudhry, P, Hafner, N, Runnebaum, IB, and Hennessy, BT

Abstract

BACKGROUND: BRCA1 methylation has been associated with homologous recombination deficiency, a biomarker of platinum sensitivity. Studies evaluating BRCA1-methylated tubal and ovarian cancer (OC) do not consistently support improved survival following platinum chemotherapy. We examine the characteristics of BRCA1-methylated OC in a meta-analysis of individual participant data. METHODS: Data of 2636 participants across 15 studies were analyzed. BRCA1-methylated tumors were defined according to their original study. Associations between BRCA1 methylation and clinicopathological characteristics were evaluated. The effects of methylation on overall survival (OS) and progression-free survival (PFS) were examined using mixed-effects models. All statistical tests were 2-sided. RESULTS: 430 (16.3%) tumors were BRCA1-methylated. BRCA1 methylation was associated with younger age and advanced-stage, high-grade serous OC. There were no survival differences between BRCA1-methylated and non-BRCA1-methylated OC (median PFS = 20.0 vs 18.5 months, hazard ratio [HR] = 1.01, 95% CI = 0.87 to 1.16; P = .98; median OS = 46.6 vs 48.0 months, HR = 1.02, 95% CI = 0.87 to 1.18; P = .96). Where BRCA1/2 mutations were evaluated (n = 1248), BRCA1 methylation displayed no survival advantage over BRCA1/2-intact (BRCA1/2 wild-type non-BRCA1-methylated) OC. Studies used different methods to define BRCA1 methylation. Where BRCA1 methylation was determined using methylation-specific polymerase chain reaction and gel electrophoresis (n = 834), it was associated with improved survival (PFS: HR = 0.80, 95% CI = 0.66 to 0.97; P = .02; OS: HR = 0.80, 95% CI = 0.63 to 1.00; P = .05) on mixed-effects modeling. CONCLUSION: BRCA1-methylated OC displays similar clinicopathological features to BRCA1-mutated OC but is not associated with survival. Heterogeneity within BRCA1 methylation assays influences associations. Refining these assays may better identify cases with silenced BRCA1 function and improved patien

Published
2020

28. Role of pelvic lymph node resection in vulvar cancer – a subset analysis of the AGO-CaRE-1 study

Author

Woelber, L, additional, Bommert, M, additional, Harter, P, additional, Prieske, K, additional, zu Eulenburg, C, additional, Jueckstock, J, additional, Hilpert, F, additional, de Gregorio, N, additional, Iborra, S, additional, Sehouli, J, additional, Ignatov, A, additional, Hillemanns, P, additional, Fuerst, S, additional, Strauss, HG, additional, Baumann, K, additional, Thiel, F, additional, Mustea, A, additional, Meier, W, additional, Wimberger, P, additional, Hanker, L, additional, Schmalfeldt, B, additional, Canzler, U, additional, Fehm, T, additional, Luyten, A, additional, Hellriegel, M, additional, Kosse, J, additional, Heiss, C, additional, Hantschmann, P, additional, Mallmann, P, additional, Tanner, B, additional, Pfisterer, J, additional, Mahner, S, additional, and Jaeger, A, additional

Published
2020
Full Text
View/download PDF

30. The influence of age on treatment and prognosis of patients with squamous cell vulvar cancer (VSCC)- a subset analysis of the AGO-CaRE-1 study

Author

Prieske, K, additional, Woelber, L, additional, Muallem, M.Z, additional, Eulenburg, C, additional, Jückstock, J, additional, Hilpert, F, additional, de Gregorio, N, additional, Iborra, S, additional, Ignatov, A, additional, Hillemanns, P, additional, Fuerst, S.T, additional, Strauss, H.G, additional, Baumann, K, additional, Thiel, F, additional, Mustea, A, additional, Meier, W, additional, Harter, P, additional, Wimberger, P, additional, Hanker, L, additional, Schmalfeldt, B, additional, Canzler, U, additional, Fehm, T, additional, Luyten, A, additional, Hellriegel, M, additional, Kosse, J, additional, Heiss, C, additional, Hantschmann, P, additional, Mallmann, P, additional, Tanner, B, additional, Pfisterer, J, additional, Sehouli, J, additional, and Mahner, S, additional

Published
2020
Full Text
View/download PDF

31. LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study

Author

Coleman, R.L., primary, Lorusso, D., additional, Gennigens, C., additional, González-Martín, A., additional, Randall, L., additional, Cibula, D., additional, Lund, B., additional, Woelber, L., additional, Pignata, S., additional, Forget, F., additional, Redondo, A., additional, Rangwala, R., additional, Vindeløv, S.D., additional, Chen, M., additional, Harris, J.R., additional, Nicacio, L., additional, Teng, M.S.L., additional, Smith, M., additional, Monk, B.J., additional, and Vergote, I.B., additional

Published
2020
Full Text
View/download PDF

32. Bedeutung der pelvinen Lymphonodektomie beim Plattenepithelkarzinom der Vulva (VSCC) – Subgruppenanalyse der AGO-CaRE-1 Studie

Author

Jueckstock, J, additional, Fuerst, S, additional, Bommert, M, additional, Harter, P, additional, Prieske, K, additional, Eulenburg, C, additional, Hilpert, F, additional, deGregorio, N, additional, Iborra, S, additional, Sehouli, J, additional, Ignatov, A, additional, Hillemanns, P, additional, Jaeger, A, additional, Strauss, H-G, additional, Baumann, K, additional, Thiel, F, additional, Mustea, A, additional, Meier, W, additional, Wimberger, P, additional, Hanker, L, additional, Schmalfeldt, B, additional, Canzler, U, additional, Fehm, T, additional, Luyten, A, additional, Hellriegel, M, additional, Kosse, J, additional, Heiss, C, additional, Hantschmann, P, additional, Mallmann, P, additional, Tanner, B, additional, Pfisterer, J, additional, Woelber, L, additional, and Mahner, S, additional

Published
2020
Full Text
View/download PDF

33. Surgical management of peritoneal carcinomatosis in ovarian cancer

Author

Rafii A, Masson, Philipp Harter, S. B. Lee, Parga K, Eisenkop Sm, Z-Y. Zhang, Hoskins Wj, Romano F, Lueck Hj, Rouzier R, Chereau E, Puri I, Bristow Re, Morgan Va, Dowdy Sc, Li Zt, Collins Dj, Eulenburg C, Lang J, Griffiths Ct, Tomacruz Rs, Eric L. Eisenhauer, Rongyu Zang, Braicu Ei, Giacomo Aletti, Brady Mf, Woelber L, Gostout, McGuire Wp, Berek Js, Friedman Rl, Chi Ds, Armstrong Dk, Ballester M, Memarzadeh S, and Venkatraman Es

Subjects
Oncology, medicine.medical_specialty, business.industry, Internal medicine, medicine, Ovarian cancer, medicine.disease, business, Peritoneal carcinomatosis
Published
2014

34. Preoperative c-reactive protein and thrombocyte count as potential markers for longterm survival in ovarian cancer

Author

Braicu, E.I., primary, Sehouli, J., additional, Richter, R., additional, Vergote, I.B., additional, Concin, N., additional, van Nieuwenhuysen, E., additional, Achimas, P., additional, Berger, A., additional, Fetica, B., additional, Mahner, S., additional, Glajzer, J., additional, Papadia, A., additional, Woelber, L., additional, Gasparri, M.L., additional, Vanderstichele, A., additional, Benedetti Panici, P., additional, Mueller, M., additional, Ruscito, I., additional, Zimmer, J., additional, and Woopen, H., additional

Published
2018
Full Text
View/download PDF

39. European society of gynaecological oncology guidelines for the management of patients with Vulvar cancer

Author

Oonk, M, Planchamp, F, Baldwin, P, Bidzinski, M, Brännström, M, Landoni, F, Mahner, S, Mahantshetty, U, Mirza, M, Petersen, C, Querleu, D, Regauer, S, Rob, L, Rouzier, R, Ulrikh, E, Van Der Velden, J, Vergote, I, Woelber, L, Van Der Zee, A, Oonk, MHM, Van Der Zee, AGJ, Oonk, M, Planchamp, F, Baldwin, P, Bidzinski, M, Brännström, M, Landoni, F, Mahner, S, Mahantshetty, U, Mirza, M, Petersen, C, Querleu, D, Regauer, S, Rob, L, Rouzier, R, Ulrikh, E, Van Der Velden, J, Vergote, I, Woelber, L, Van Der Zee, A, Oonk, MHM, and Van Der Zee, AGJ

Abstract

The aim of this study was to develop clinically relevant and evidence-based guidelines as part of European Society of Gynaecological Oncology's mission to improve the quality of care for women with gynecologic cancers across Europe. Methods: The European Society of Gynaecological Oncology Council nominated an international development group made of practicing clinicians who provide care to patients with vulvar cancer and have demonstrated leadership and interest in the management of patients with vulvar cancer (18 experts across Europe). To ensure that the statements are evidence based, the current literature identified from a systematic search has been reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group (expert agreement). The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 181 international reviewers including patient representatives independent from the development group. Results: The guidelines cover diagnosis and referral, preoperative investigations, surgical management (local treatment, groin treatment including sentinel lymph node procedure, reconstructive surgery), radiation therapy, chemoradiation, systemic treatment, treatment of recurrent disease (vulvar recurrence, groin recurrence, distant metastases), and follow-up.

Published
2017

40. The exposure-response relationship of niraparib in patients with gBRCAmut and non-gBRCAmut: Results from the ENGOT-OV16/NOVA Trial

Author

Wang, J., primary, Zhang, Z-Y., additional, Mirza, M.R., additional, Gilbert, L., additional, Fabbro, M., additional, Tinker, A.V., additional, Wang, X., additional, Redondo, A., additional, Berek, J.S., additional, Woelber, L., additional, Pentikis, H.S., additional, Moore, K.N., additional, Lorusso, D., additional, Benigno, B., additional, Hazard, S.J., additional, Follana, P., additional, Rimel, B.J., additional, Matulonis, U.A., additional, Agarwal, S., additional, and Kansra, V., additional

Published
2017
Full Text
View/download PDF

41. Diagnosis, Therapy and Follow-up Care of Vulvar Cancer and its Precursors. Guideline of the DGGG and DKG (S2k-Level, AWMF Registry Number 015/059, November 2015

Author

Schnuerch, H. G., Ackermann, S., Alt, C. D., Barinoff, J., Boeing, C., Dannecker, C., Gieseking, F., Guenthert, A., Hantschmann, P., Horn, L. C., Kuerzl, R., Mallmann, P., Marnitz, S., Mehlhorn, G., Hack, C. C., Koch, M. C., Torsten, U., Weikel, W., Woelber, L., Hampl, M., Schnuerch, H. G., Ackermann, S., Alt, C. D., Barinoff, J., Boeing, C., Dannecker, C., Gieseking, F., Guenthert, A., Hantschmann, P., Horn, L. C., Kuerzl, R., Mallmann, P., Marnitz, S., Mehlhorn, G., Hack, C. C., Koch, M. C., Torsten, U., Weikel, W., Woelber, L., and Hampl, M.

Abstract

Purpose: This is an official guideline, published and coordinated by the Arbeitsgemeinschaft Gynakologische Onkologie (AGO, Study Group for Gynecologic Oncology) of the Deutsche Krebsgesellschaft (DKG, German Cancer Society) and the Deutsche Gesellschaft fur Gynakologie und Geburtshilfe (DGGG, German Society for Gynecology and Obstetrics). The number of cases with vulvar cancer is on the rise, but because of the former rarity of this condition and the resulting lack of literature with a high level of evidence, in many areas knowledge of the optimal clinical management still lags behind what would be required. This updated guideline aims to disseminate the most recent recommendations, which are much clearer and more individualized, and is intended to create a basis for the assessment and improvement of quality care in hospitals. Methods: This S2k guideline was drafted by members of the AGO Committee on Vulvar and Vaginal Tumors; it was developed and formally completed in accordance with the structured consensus process of the Association of Scientific Medical Societies in Germany (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, AWMF). Recommendations: 1. The incidence of disease must be taken into consideration. 2. The diagnostic pathway, which is determined by the initial findings, must be followed. 3. The clinical and therapeutic management of vulvar cancer must be done on an individual basis and depends on the stage of disease. 4. The indications for sentinel lymph node biopsy must be evaluated very carefully. 5. Follow-up and treatment for recurrence must be adapted to the individual case.

Published
2016

43. Patterns of distant metastases in vulvar cancer

Author

Prieske, K, primary, Haeringer, N, additional, Grimm, D, additional, Trillsch, F, additional, Eulenburg, C, additional, Burandt, E, additional, Schmalfeldt, B, additional, Mahner, S, additional, Mueller, V, additional, and Woelber, L, additional

Published
2016
Full Text
View/download PDF

47. Surgical staging and prognosis in serous borderline ovarian tumours (BOT): A subanalysis of the AGO ROBOT study

Author

Trillsch, F, primary, Mahner, S, additional, Vettorazzi, E, additional, Woelber, L, additional, Reuss, A, additional, Baumann, K, additional, Keyver-Paik, M-D, additional, Canzler, U, additional, Wollschlaeger, K, additional, Forner, D, additional, Pfisterer, J, additional, Schroeder, W, additional, Muenstedt, K, additional, Richter, B, additional, Fotopoulou, C, additional, Schmalfeldt, B, additional, Burges, A, additional, Ewald-Riegler, N, additional, de Gregorio, N, additional, Hilpert, F, additional, Fehm, T, additional, Meier, W, additional, Hillemanns, P, additional, Hanker, L, additional, Hasenburg, A, additional, Strauss, H-G, additional, Hellriegel, M, additional, Wimberger, P, additional, Kommoss, S, additional, Kommoss, F, additional, Hauptmann, S, additional, and du Bois, A, additional

Published
2015
Full Text
View/download PDF

49. AGO Vulva CaRE-1 multicenter study - adjuvant radio(chemo)therapy in vulvar cancer

Author

Hillemanns, P., Woelber, L., Jueckstock, J., Neuser, P., Hilpert, F., Harter, P., De Gregorio, N., Hasenburg, A., Sehouli, J., Habermann, A., Fuerst, S. T., Strauss, H. -G., Baumann, K., Thiel, F., Mustea, A., Meier, W., Du Bois, A., Wimberger, P., Hanker, L., Schmalfeldt, B., Canzler, U., Fehm, T., Luyten, A., Hellriegel, M., Kosse, J., Heiss, C., Hantschmann, P., Mallmann, P., Tanner, B., Pfisterer, J., Richter, B., Petersen, C., Mahner, S., Hillemanns, P., Woelber, L., Jueckstock, J., Neuser, P., Hilpert, F., Harter, P., De Gregorio, N., Hasenburg, A., Sehouli, J., Habermann, A., Fuerst, S. T., Strauss, H. -G., Baumann, K., Thiel, F., Mustea, A., Meier, W., Du Bois, A., Wimberger, P., Hanker, L., Schmalfeldt, B., Canzler, U., Fehm, T., Luyten, A., Hellriegel, M., Kosse, J., Heiss, C., Hantschmann, P., Mallmann, P., Tanner, B., Pfisterer, J., Richter, B., Petersen, C., and Mahner, S.

Published
2014

50. Outcome parameters in node-negative vulvar cancer - subset analysis of the AGO CaRE-1 study

Author

Woelber, L., Jueckstock, J., Hilpert, F., Neuser, P., Harter, P., De Gregorio, N., Iborra, S., Sehouli, J., Habermann, A., Hillemanns, P., Fuerst, S., Strauss, H. -G., Baumann, K. H., Thiel, F., Mustea, A., Meier, W., Du Bois, A., Wimberger, P., Hanker, L. C., Schmalfeldt, B., Canzler, U., Fehm, T., Luyten, A., Hellriegel, M., Kosse, J., Heiss, C., Hantschmann, P., Mallmann, P., Tanner, B., Pfisterer, J., Richter, B., Griebel, L. -F., Mahner, S., Woelber, L., Jueckstock, J., Hilpert, F., Neuser, P., Harter, P., De Gregorio, N., Iborra, S., Sehouli, J., Habermann, A., Hillemanns, P., Fuerst, S., Strauss, H. -G., Baumann, K. H., Thiel, F., Mustea, A., Meier, W., Du Bois, A., Wimberger, P., Hanker, L. C., Schmalfeldt, B., Canzler, U., Fehm, T., Luyten, A., Hellriegel, M., Kosse, J., Heiss, C., Hantschmann, P., Mallmann, P., Tanner, B., Pfisterer, J., Richter, B., Griebel, L. -F., and Mahner, S.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results